Experiences with
Obinutuzumab358 public posts
MsLockYourPosts aka Pat Kennedy aka PKenn has passed away.
the CLL Forum approximately 2010, where she and fellow Californian- FoothillLynn / E-Lynn[i] [/i] contributed many replies and experiences that helped me climb the steep CLL learning curve, eventually those two became the "Gazyva Girls" some of the first patients to be treated with Gazyva / Obinutuzumab
From the CLL14 Study: Venetoclax Plus Obinutuzumab Prolongs Progression Free Survival, Not Overall Survival , in CLL
plus obinutuzumab or chlorambucil plus obinutuzumab.
Want to take advantage of all our features? Just log in!
or
Frontline Ibrutinib/Venetoclax Elicits Durable Responses in CLL With Undetectable MRD
Fixed duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study.
The Leukemia & Lymphoma Society’s National Patient Registry COVID-19 vaccination antibody results - published today (Greenberg et al)
cytotoxic chemotherapy 71
Obinutuzumab, ibrutinib 70
Obinutuzumab, acalabrutinib 66
Rituximab 63
Acalabrutinib 55
Ibrutinib 48
Ibrutinib, IVIG 40
IVIG 25
Source: The LLS National Patient Registry.
Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients
In addition, they may experience:
• Treatment-related immunodeficiency (such as that resulting from anti-CD20 monoclonal antibody treatment such as Rituximab (Mabthera/Rituxan), Obinutuzumab (Gazyva) or ofatumumab (Arzerra)
In a recent study, ‘individual risk factors associated with a poor prognosis
News - Acalabrutinib approved for Restricted use in Scotland
[/i]
Evidence presented showed that Acalabrutinib, compared with chlorambucil-obinutuzumab, significantly improved progression-free survival in adults with previously untreated CLL with co-morbidities.
Jackie